prescription patterns

处方模式
  • 文章类型: Published Erratum
    [这更正了文章DOI:10.3389/fhar.2023.1291900。].
    [This corrects the article DOI: 10.3389/fphar.2023.1291900.].
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:由于情感障碍的高患病率和相关痛苦,情感障碍对公共卫生造成了重大负担。本研究通过提供对药物使用趋势的见解,解决了当前文献和临床实践中的差距。这可以告知治疗策略和优化患者护理。该研究旨在调查药物利用模式,特别关注定义的每日剂量/1000/天,在三级护理医院精神科门诊就诊的个人中。
    方法:这个横截面,前瞻性药物利用研究包括600名18岁及以上的情感障碍患者。研究期为12个月,从2021年3月到2022年2月。人口统计数据,诊断,治疗,和咨询进行收集和分析,采用描述性统计。
    结果:在分析的600名患者中,双相情感障碍是最普遍的(239名患者,39.83%),其次是抑郁症(208名患者,34.67%)。三联疗法是最常见的处方方案,占308次遭遇(51.33%)。每次遇到的平均药物数量为3.75±1.01。为594名患者或其亲属提供了心理治疗和药物咨询相结合的课程,占总遭遇的99%。
    结论:该研究强调了三联疗法在控制情感障碍方面的普遍应用,尤其是双相情感障碍和躁狂症。有效利用基本药物清单和全面的患者咨询强调了精神科门诊环境中整体护理的重要性。
    结论:鉴于三联疗法的高患病率,有必要进一步研究这种治疗方法的有效性和安全性.此外,继续强调患者教育和咨询可以提高情感障碍患者的治疗依从性和总体结局.
    BACKGROUND: Affective disorders impose a significant burden on public health due to their high prevalence and associated suffering. This study addresses gaps in current literature and clinical practice by providing insights into medication usage trends, which can inform treatment strategies and optimize patient care. The study aims to investigate drug utilization patterns, particularly focusing on defined daily dose/1000/day, among individuals attending a psychiatric outpatient department of a tertiary care hospital.
    METHODS: This cross-sectional, prospective drug utilization study included 600 affective disorder patients aged 18 years and above. The study period spanned 12 months, from March 2021 to February 2022. Data on demographics, diagnosis, treatment, and counseling were collected and analyzed using descriptive statistics.
    RESULTS:  Among the 600 patients analyzed, bipolar mood disorder was the most prevalent (239 patients, 39.83%), followed by depressive disorder (208 patients, 34.67%). Triple therapy was the most common prescription regimen, accounting for 308 encounters (51.33%). The average number of drugs per encounter was 3.75 ± 1.01. A combination of psychotherapy and medication counseling sessions was provided to 594 patients or their relatives, representing 99% of the total encounters.
    CONCLUSIONS: The study highlights the prevalent use of triple therapy in managing affective disorders, especially bipolar mood disorder and mania disorder. Effective utilization of essential drug lists and comprehensive patient counseling underscores the importance of holistic care in psychiatric outpatient settings.
    CONCLUSIONS:  Given the high prevalence of triple therapy, further research into the efficacy and safety of this treatment approach is warranted. Additionally, continued emphasis on patient education and counseling can enhance treatment adherence and overall outcomes in individuals with affective disorders.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    (1)目的:本研究旨在评估在阿曼一家三级医院寻求护理的成年患者中注意力缺陷多动障碍(ADHD)的5年患病率和临床特征。(2)方法:采用描述性和推断性统计方法对数据进行分析,并计算出标准化的患病率估计值。(3)结果:在39,881次医院就诊中,1.77%的患者为ADHD患者。这相当于每1000名门诊患者17.8次就诊。2021年是所考虑的五年中患病率最高的一年,而2020年的患病率最低。尽管年龄分布表明,“20岁以下”年龄组的患病率最高,性别分布显示,ADHD在成年男性中更为常见.在多动症的各种亚型中,注意力不集中是最常见的。(4)结论:本研究特别比较了同期患有ADHD的成年队列与其他精神病诊所参与者之间的患病率和相关因素。该研究提供了有关正在考虑的人群中成人ADHD的患病率和临床特征的重要信息。
    (1) Objectives: This study aimed to assess the 5-year prevalence and clinical profile of attention deficit hyperactive disorder (ADHD) among adult patients seeking care in a tertiary care hospital in Oman. (2) Methods: The data were analysed using descriptive and inferential statistics and standardised prevalence estimates were calculated. (3) Results: Of the 39,881 hospital visits, 1.77% were made by adults with ADHD. This is equivalent to 17.8 visits per 1000 outpatients. The year 2021 saw the highest prevalence among the five years considered, while 2020 had the lowest prevalence. Although the age distribution indicated that the age group \'under 20\' had the highest prevalence, the gender distribution showed that ADHD was more common among adult men. Among the various subtypes of ADHD, inattention was the most common. (4) Conclusions: This study specifically compared the prevalence and associated factors between an adult cohort with ADHD and those other psychiatric clinic attendees during the same period. The study offers important information on the prevalence and clinical profile of adults with ADHD in the population under consideration.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    抗血栓药物已广泛用于治疗和预防COVID-19相关的血栓形成;然而,关于它们在人口水平上的使用的研究是有限的。我们的目的是描述西班牙初级保健和住院COVID-19患者在大流行期间的抗血栓使用模式。方法:进行了真实世界的数据研究。数据来自BIFAP的电子健康记录。我们调查了2020年3月至2022年2月之间诊断后±14天内的抗血栓处方,将其分为先前和新/幼稚组,并报告了他们出院后的使用情况。结果:我们包括882,540名个体(53.4%的女性),其中78,499人住院。中位年龄为44.7岁(IQR39-59)。在37,183(4.6%)初级保健受试者和42,041(53.6%)住院患者中规定了抗血栓药,其中7505人(20.2%)和20,300人(48.3%),分别,是天真的用户。与新用户相比,以前的用户年龄更大,并且有更多的合并症。依诺肝素是医院处方最多的抗血栓药物,新用户的处方率高于以前的用户(2348.2,IQR2390-3123.1与1378,IQR1162-1751.6处方/10,000例,p=0.002)。在初级保健中,乙酰水杨酸是最常用的抗血栓药,在之前的使用率高于天真的用户。出院后使用发生在6686名(15.9%)受试者中(使用中位数=10天,IQR9-30)。结论:我们的研究确定了在COVID-19患者中处方抗血栓药物的共识,但医院使用率低。
    Antithrombotics have been widely used to treat and prevent COVID-19-related thrombosis; however, studies on their use at population levels are limited. We aimed to describe antithrombotic use patterns during the pandemic in Spanish primary care and hospital-admitted patients with COVID-19. Methods: A real-world data study was performed. Data were obtained from BIFAP\'s electronic health records. We investigated the antithrombotic prescriptions made within ±14 days after diagnosis between March 2020 and February 2022, divided their use into prior and new/naive groups, and reported their post-discharge use. Results: We included 882,540 individuals (53.4% women), of whom 78,499 were hospitalized. The median age was 44.7 (IQR 39-59). Antithrombotics were prescribed in 37,183 (4.6%) primary care subjects and 42,041 (53.6%) hospital-admitted patients, of whom 7505 (20.2%) and 20,300 (48.3%), respectively, were naive users. Prior users were older and had more comorbidities than new users. Enoxaparin was the most prescribed antithrombotic in hospitals, with higher prescription rates in new than prior users (2348.2, IQR 2390-3123.1 vs. 1378, IQR 1162-1751.6 prescriptions per 10,000 cases, p = 0.002). In primary care, acetylsalicylic acid was the most used antithrombotic, with higher use rates in prior than in naïve users. Post-discharge use occurred in 6686 (15.9%) subjects (median use = 10 days, IQR 9-30). Conclusions: Our study identified a consensus on prescribing antithrombotics in COVID-19 patients, but with low use rates in hospitals.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    泌乳不足是全球哺乳母亲面临的普遍挑战。人们对使用草药半乳糖苷来增强泌乳越来越感兴趣,但它们的治疗效果和潜在机制需要彻底调查。本研究旨在通过利用现实世界数据并采用网络分析方法,研究草药半乳糖凝液在解决泌乳不足方面的功效和作用机制。
    我们的回顾性研究使用台湾的纵向健康保险数据库2000(LHID2000)来确定从2000年到2018年诊断为泌乳功能不全的490名患者。我们分析了人口学特征,共存的疾病,以及中草药产品(CHP)使用者和非使用者的处方模式。此外,我们利用网络分析方法来探索最常用的CHP中的潜在化合物和靶标,王部刘星和陆路通草对(WLHP)组合。
    在490名患者中,81%是CHP用户。CHP用户和非用户之间的人口统计学特征没有显着差异,但是我们观察到共存疾病的患病率存在明显差异。对CHP处方的详细检查显示WLHP占主导地位,促使进一步调查。综合分析确定了WLHP中的29种主要化合物,与215个独特目标相关。交叉分析显示WLHP和泌乳之间有101个重叠目标,提示它们作为泌乳不足治疗的治疗靶点的潜力。蛋白质-蛋白质相互作用(PPI)网络的拓扑分析确定了13个可能对WLHP的治疗效果至关重要的hub基因。功能富集分析表明,这些靶标参与了关键的泌乳调控途径,包括PI3K-Akt信号通路,催乳素信号通路,雌激素信号通路,和AMPK信号通路。
    这项研究强调了热电联产的潜力,特别是WLHP组合,管理泌乳不足。多化合物,WLHP的多靶标方法及其与关键生物过程和信号通路的相互作用为其治疗效果的潜在机制提供了有价值的见解。这些发现值得进一步的实验验证,并可以指导CHP在泌乳不足治疗中的未来研究和临床应用。
    UNASSIGNED: Lactation insufficiency is a prevalent challenge for nursing mothers globally. There is a growing interest in the use of herbal galactagogues for enhancing lactation, but their therapeutic efficacy and underlying mechanisms need thorough investigation. This study aims to investigate the efficacy and mechanisms of action of herbal galactagogues in addressing lactation insufficiency by utilizing real-world data and employing a network analysis approach.
    UNASSIGNED: Our retrospective study used Taiwan\'s Longitudinal Health Insurance Database 2000 (LHID2000) to identify 490 patients diagnosed with lactation insufficiency from 2000 to 2018. We analyzed demographic characteristics, co-existing diseases, and prescription patterns for both users and non-users of Chinese herbal products (CHP). Additionally, we utilized a network analysis approach to explore potential compounds and targets in the most frequently used CHP, the Wang Bu Liu Xing and Lu Lu Tong herb pair (WLHP) combination.
    UNASSIGNED: Out of 490 patients, 81% were CHP users. There were no significant differences in demographic characteristics between CHP users and non-users, but we observed a notable divergence in the prevalence of co-existing diseases. A detailed examination of CHP prescriptions revealed the predominance of WLHP, prompting further investigation. Comprehensive analysis identified 29 major compounds in WLHP, which were associated with 215 unique targets. Intersection analysis revealed 101 overlapping targets between WLHP and lactation, suggesting their potential as therapeutic targets for lactation insufficiency treatment. Topological analysis of the protein-protein interaction (PPI) network identified 13 hub genes potentially crucial for the therapeutic effect of WLHP. Functional enrichment analysis showed that these targets were involved in critical lactation regulation pathways, including the PI3K-Akt signaling pathway, prolactin signaling pathway, estrogen signaling pathway, and AMPK signaling pathway.
    UNASSIGNED: This study emphasizes the potential of CHP, specifically the WLHP combination, in managing lactation insufficiency. The multi-compound, multi-target approach of WLHP and its interaction with key biological processes and signaling pathways offer valuable insights into the underlying mechanisms of its therapeutic effects. These findings warrant further experimental validation and can guide future research and clinical applications of CHP in lactation insufficiency treatment.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:在澳大利亚,短效β2-激动剂(SABA)可以在非处方(OTC)和处方上使用。这种访问的便利性可能会影响澳大利亚人口中SABA的使用。我们的目标是评估处方的模式和结果关联,获得了OTC,并报告了患有哮喘的澳大利亚人使用SABA。
    方法:这是一项横断面研究,使用来自初级保健电子病历(EMR)的数据和澳大利亚最佳患者护理研究数据库(OPCRDA)中完成的患者问卷.共纳入720名年龄≥12岁且在其EMR中诊断为哮喘并接受哮喘治疗的个体。根据处方授权的SABA吸入器的年度数量,收购场外交易并报告,并调查了与自我报告的急性加重和哮喘控制的相关性。
    结果:92.9%(n=380/409)的发放SABA处方的个人每年被授权使用≥3个吸入器,尽管这与自我报告的用法不同。在过去12个月中报告使用SABA的个体中(n=546),37.0%报告使用≥3个吸入器。与报告使用1-2个SABA吸入器的患者相比,这些报告SABA过度使用的患者经历了2.52倍(95%置信区间[CI]1.73-3.70)的严重加重和4.51倍(95%CI3.13-6.55)的哮喘控制差。未按处方接受SABA的患者(43.2%;n=311/720)也比1-2吸入器的患者严重加重了2.71倍(95%CI1.07-7.26)。在这些病人中,38.9%报告使用OTCSABA和其他处方药,26.4%的人报告使用SABAOTC作为他们唯一的哮喘药物,13.2%的人接受了其他治疗,但不是SABAOTC,14.5%的人没有使用任何药物。
    结论:自我报告的SABA过度使用和SABA处方为零与哮喘预后不良相关。处方授权之间的脱节,OTC可用性和实际使用情况,使临床医生难以量化SABA的使用。
    BACKGROUND: In Australia, short-acting β2-agonists (SABA) are available both over the counter (OTC) and on prescription. This ease of access may impact SABA use in the Australian population. Our aim was to assess patterns and outcome associations of prescribed, acquired OTC and reported use of SABA by Australians with asthma.
    METHODS: This was a cross-sectional study, using data derived from primary care electronic medical records (EMRs) and patient completed questionnaires within Optimum Patient Care Research Database Australia (OPCRDA). A total of 720 individuals aged ≥ 12 years with an asthma diagnosis in their EMRs and receiving asthma therapy were included. The annual number of SABA inhalers authorised on prescription, acquired OTC and reported, and the association with self-reported exacerbations and asthma control were investigated.
    RESULTS: 92.9% (n = 380/409) of individuals issued with SABA prescription were authorised ≥ 3 inhalers annually, although this differed from self-reported usage. Of individuals reporting SABA use (n = 546) in the last 12 months, 37.0% reported using ≥ 3 inhalers. These patients who reported SABA overuse experienced 2.52 (95% confidence interval [CI] 1.73-3.70) times more severe exacerbations and were 4.51 times (95% CI 3.13-6.55) more likely to have poor asthma control than those who reported using 1-2 SABA inhalers. Patients who did not receive SABA on prescription (43.2%; n = 311/720) also experienced 2.71 (95% CI 1.07-7.26) times more severe exacerbations than those prescribed 1-2 inhalers. Of these patients, 38.9% reported using OTC SABA and other prescription medications, 26.4% reported using SABA OTC as their only asthma medication, 13.2% were prescribed other therapies but not SABA OTC and 14.5% were not using any medication.
    CONCLUSIONS: Both self-reported SABA overuse and zero SABA prescriptions were associated with poor asthma outcomes. The disconnect between prescribing authorisation, OTC availability and actual use, make it difficult for clinicians to quantify SABA use.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:调查欧洲常规临床实践中精神药物使用者与非精神药物使用者的联合口服避孕药(COC)的处方模式。
    方法:对三个大型,prospective,多国队列研究,包括来自12个欧洲国家的接受COC新处方的女性。我们计算了标准化平均差异(SMD),以调查精神药物使用(使用/不使用)或精神药物类别(精神药物/精神药物)的状态是否与医疗保健专业人员选择特定类型的COC孕激素有关。
    结果:我们的分析包括143,069名非精神药物使用者和2,174名精神药物使用者。在队列中频率最高的孕激素是左炔诺孕酮(非精神药物使用者:33.8%;精神药物使用者:32.4%),诺美孕酮/醋酸诺美孕酮(非精神药物使用者:19.1%;精神药物使用者:26.4%),和屈螺酮(非精神药物使用者:15.9%;精神药物使用者:14.8%)。SMD分析表明,两组之间的COC处方模式没有实质性差异。然而,我们观察到草药抗抑郁药圣约翰草使用者的关联信号,与非精神药物使用者相比,这些人更经常接受屈螺酮处方,而服用诺米孕酮/醋酸诺米孕酮的频率更低.
    结论:精神药物使用者状况似乎并不影响医护专业人员开COC处方时的决定。然而,有限的证据表明,药物相互作用的风险可能因孕激素类型而异,某些COC可能比其他COC更适合精神药物使用者。应将具体指南传达给医疗保健专业人员,以协助他们进行避孕咨询。
    结论:除了圣约翰麦汁,我们的分析显示,在精神药物使用者和非使用者中,联合口服避孕药的处方行为没有差异。然而,医疗保健专业人员应在避孕咨询中仔细考虑精神药物的使用,因为目前尚不清楚与某些口服避孕药合用时是否存在药物相互作用.
    To investigate prescription patterns of combined oral contraceptives (COC) among psychotropic drug users compared to non-psychotropic drug users in routine clinical practice in Europe.
    A pooled analysis of three large, prospective, multinational cohort studies including women with a new prescription of COC from 12 European countries. We calculated standardized mean differences (SMD) to investigate whether the status of psychotropic drug use (use/no use) or the psychotropic drug class (psycholeptics/psychoanaleptics) is associated with the healthcare professional\'s choice of a specific type of COC progestin.
    Our analysis comprised 143,069 non-psychotropic drug users and 2174 psychotropic drug users. Progestins with the highest frequency in the cohorts were levonorgestrel (non-psychotropic drug users: 33.8%; psychotropic drug users: 32.4%), nomegestrol/nomegestrol acetate (non-psychotropic drug users: 19.1%; psychotropic drug users: 26.4%), and drospirenone (non-psychotropic drug users: 15.9%; psychotropic drug users: 14.8%). SMD analysis indicated no substantial differences in COC prescription patterns between the two cohorts. However, we observed association signals for users of the herbal antidepressant St. John\'s wort in that those individuals more often received a prescription for drospirenone and less frequently for nomegestrol/nomegestrol acetate compared to non-psychotropic drug users.
    Psychotropic drug user status does not seem to affect healthcare professionals\' decisions when prescribing COC. However, limited evidence suggests that the risk for drug interactions might differ by progestin type, and some COC might be more suitable for psychotropic drug users than others. Specific guidelines should be conveyed to healthcare professionals to assist them in contraceptive counseling.
    With exception of St. John\'s wort, our analysis showed no differential prescription behavior of combined oral contraceptives in psychotropic drug users and non-users. However, healthcare professionals should carefully consider psychotropic drug use in contraceptive counseling as it is still unclear whether drug interactions exist when co-administered with certain oral contraceptives.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    2019年冠状病毒病(COVID-19)大流行导致生命终结时复杂的身体和心理社会症状负担。在其他疾病状态下,专家姑息治疗投入的好处已经确立,然而,几乎没有证据表明,在死于COVID-19的患者中,这些服务的转诊模式。
    这项回顾性审计调查了2022年在南澳大利亚一家四级医院(皇家阿德莱德医院)死于COVID-19的患者的转诊模式,以及人口统计学特征或COVID-19特定因素是否对这些患者是否接受专科姑息治疗服务(PCS)产生影响。第二个目标是确定患者生命最后24小时的处方模式,以及这是否受到转诊的影响。
    数据是从电子病历中获得的,并根据各种预测因素,使用二元逻辑回归分析转诊至PCS与不转诊。
    患者人口统计学或COVID-19特异性因素与转诊PCS相比没有显着差异。死亡前24小时接受转诊的患者与口服吗啡等效日剂量(OMEDD)较高的患者之间有统计学意义。以及持续皮下输注的存在。尽管这种关系的原因尚不确定,它可能代表了姑息治疗医师在会诊期间的处方模式,或提示转诊的潜在更高的症状负担.与其他阿片类药物相比,接受氢吗啡酮的患者比例也更高,尽管OMEDD与其他已发表的文献一致。
    UNASSIGNED: The coronavirus disease 2019 (COVID-19) pandemic resulted in complex physical and psychosocial symptom burden at end of life. The benefit of specialist palliative care input in other disease states has been established, however, there is little evidence on referral patterns to these services in patients dying from COVID-19.
    UNASSIGNED: This retrospective audit investigated the referral patterns for patients who died from COVID-19 at a quaternary hospital in South Australia (the Royal Adelaide Hospital) over a six-month period in 2022, and whether demographic features or COVID-19 specific factors had an impact on whether these patients received specialist palliative care services (PCS). The second aim was to identify prescription patterns for patients in the last 24 hours of life, and whether this was impacted by referral.
    UNASSIGNED: Data were obtained from electronic medical records and analyzed using binary logistic regressions for referral to PCS versus no referral based on various predictors.
    UNASSIGNED: There was no significant difference comparing patient demographics or COVID-19 specific factors with referral to PCS. There was statistical significance between patients who received referral to PCS and those who had a higher oral morphine equivalent daily dose (OMEDD) in the 24 hours before death, as well as the presence of a continuous subcutaneous infusion. Although the cause of this relationship is undetermined, it may represent the prescription patterns of the palliative care physicians during consultation or potentially higher symptom burden prompting referral. There was also a higher proportion of patients who received hydromorphone compared with other opioids, though the OMEDD was consistent with other published literature.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    研究表明,地高辛的使用正在下降,但仍然很普遍。关于地高辛处方的最新数据和地高辛处方者的特征未知,这可以帮助理解它的当代用途。
    使用2013年至2019年的MedicareD部分数据,我们研究了地高辛处方和地高辛处方者的数量和比例的变化,整体和专业。使用逻辑回归,我们确定了与地高辛处方相关的处方特征。
    从2013年到2019年,地高辛总处方(4.6至180万张)和地高辛处方者的比例下降(总体为9.1%至4.3%;普通医学处方者为26.6%至11.8%,心脏病学为65.4%至48.9%)。从2013年开始在2019年练习的地高辛处方者中(91.2%保持活跃),59.1%根本没有开地高辛,减少31.7%,和9.2%维持或增加处方。由普通药物处方者开出的所有地高辛处方的比例从59.7%下降到48.2%,在心脏病学中增加(29%至38.5%)。在2019年的新处方者中(N=85,508),只有1.9%的人服用地高辛。与非地高辛处方者相比,地高辛处方者更可能是男性,早些时候从医学院毕业,位于中西部或南部,属于心脏病学(均P<.001)。
    地高辛处方继续下降,超过一半的2013年处方者在2019年不再处方地高辛。这可能是新的心力衰竭疗法越来越多的结果。在普通医学医生中,地高辛处方的下降幅度大于心脏病专家,建议将地高辛的使用改为专家越来越多地开出的药物。
    UNASSIGNED: Studies show that digoxin use is declining but is still prevalent. Recent data on digoxin prescription and characteristics of digoxin prescribers are unknown, which can help understand its contemporary use.
    UNASSIGNED: Using Medicare Part D data from 2013 to 2019, we studied the change in number and proportion of digoxin prescriptions and digoxin prescribers, overall and by specialty. Using logistic regression, we identified prescriber characteristics associated with digoxin prescription.
    UNASSIGNED: From 2013 to 2019, total digoxin prescriptions (4.6 to 1.8 million) and proportion of digoxin prescribers decreased (9.1% to 4.3% overall; 26.6% to 11.8% among General Medicine prescribers and 65.4% to 48.9% among Cardiology). Of digoxin prescribers from 2013 practicing in 2019 (91.2% remained active), 59.1% did not prescribe digoxin at all, 31.7% reduced, and 9.2% maintained or increased prescriptions. The proportion of all digoxin prescriptions that were prescribed by General Medicine prescribers declined from 59.7% to 48.2% and increased for Cardiology (29% to 38.5%). Among new prescribers in 2019 (N = 85,508), only 1.9% prescribed digoxin. Digoxin prescribers when compared to non-digoxin prescribers were more likely male, graduated from medical school earlier, were located in the Midwest or South, and belonged to Cardiology (all P < .001).
    UNASSIGNED: Digoxin prescriptions continue to decline with over half of 2013 prescribers no longer prescribing digoxin in 2019. This may be a result of the increasing availability of newer heart failure therapies. The decline in digoxin prescription was greater among general medicine physicians than cardiologists, suggesting a change in digoxin use to a medication prescribed increasingly by specialists.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    这项研究的目的是调查2018年至2021年位于中国西南地区的初级保健机构中全身性糖皮质激素的处方模式和使用趋势。
    在2018年至2021年间,在位于中国西南地区的32家初级保健机构中对全身性糖皮质激素处方进行了回顾性横断面分析。全身性糖皮质激素的处方被分类为适当或不适当的使用。不适当的使用进一步分为(1)不适当的适应症和(2)不适当的糖皮质激素选择。采用广义估计方程来研究与不适当使用全身性糖皮质激素有关的因素。采用季节性自回归综合移动平均(SARIMA)模型来预测不适当的糖皮质激素处方率。
    共包括203,846张(92.89%)处方,在冬季,全身糖皮质激素处方和不适当处方的数量都增加了。呼吸系统疾病(68.90%)是全身性糖皮质激素使用的最常见目标。在所有的处方中,73.18%表现出不适当的适应症,而0.05%显示选择不当。全身性糖皮质激素的使用被认为不适合呼吸系统疾病(94.19%),其次是消化系统疾病(87.75%)。内科医生,女性或33岁以下,拥有较低的教育水平和职称,并表现出不适当的全身性糖皮质激素处方的可能性较高。在65岁及以上的男性患者中,不适当使用糖皮质激素的现象更为普遍。进行模型验证后,确定SARIMA模型可用于预测中国西南地区初级保健机构中不适当的全身性糖皮质激素处方的月发生率。
    不适当使用全身性糖皮质激素仍然是初级保健机构的一个重要问题。在这方面,今后应加强医师的继续教育和专业知识培训。
    UNASSIGNED: The purpose of this study was to investigate the prescribing patterns and usage trends of systemic glucocorticoids in primary care institutions located in Southwest China from 2018 to 2021.
    UNASSIGNED: A retrospective cross-sectional analysis of systemic glucocorticoids prescriptions was conducted in 32 primary care institutions located in Southwest China between 2018 and 2021. Prescriptions of systemic glucocorticoids were classified as appropriate or inappropriate use. Inappropriate use was further classified into (1) inappropriate indications and (2) inappropriate selection of glucocorticoids. Generalized estimation equations were employed to investigate the factors associated with inappropriate utilization of systemic glucocorticoids. The seasonal autoregressive integrated moving average (SARIMA) model was employed to predict the rate of inappropriate glucocorticoids prescriptions.
    UNASSIGNED: A total of 203,846 (92.89%) prescriptions were included, both the number of systemic glucocorticoids prescriptions and inappropriate prescriptions increased in winter. Diseases of the respiratory system (68.90%) were the most frequent targets of systemic glucocorticoids use. Of all prescriptions, 73.18% exhibited inappropriate indications, while 0.05% demonstrated inappropriate selection. The utilization of systemic glucocorticoids was deemed inappropriate for diseases of the respiratory system (94.19%), followed by diseases of the digestive system (87.75%). Physicians, who were female or younger than 33 years old, possess lower levels of education and professional titles and exhibit a higher likelihood of inappropriately prescribing systemic glucocorticoids. The phenomenon of inappropriate glucocorticoids use was commoner among male patients aged 65 years and older. After conducting model verification, it was determined that the SARIMA model could be used to predict the monthly rate of inappropriate systemic glucocorticoids prescriptions in primary care institutions in southwest China.
    UNASSIGNED: The inappropriate use of systemic glucocorticoids remains a significant concern in primary care institutions. In this regard, continuing education and professional knowledge training of physicians should be strengthened in the future.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号